Navigation Links
First vaccine against fatal visceral leishmaniasis enters clinical trial
Date:2/23/2012

Seattle, WA | February 22, 2012 -- The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat diseases of poverty. The Phase 1 trial is taking place in Washington State, with a companion Phase 1 trial planned in India, an epicenter of the disease.

Visceral leishmaniasis affects vital organs and bone marrow, destroying white and red blood cells. Because VL attacks the immune system, it has been called the parasitic version of HIV/AIDS.

"Visceral leishmaniasis is a persistent and deadly global health problem," said Steve Reed, IDRI founder and Chief Scientific Officer, who led the over twenty years of preclinical vaccine work. "Our partnership with India will speed the development of an effective vaccine and accelerate its control.

Leishmaniasis takes several forms, all of which are caused by the Leishmania parasite and transmitted by infected sand flies. VL is most common in India, Nepal, Bangladesh, Sudan, and Brazil and causes about 500,000 cases and 50,000 deaths each year. Cutaneous leishmaniasis, the most common form of the disease, causes serious skin lesions and often leaves its victims permanently disfigured. Leishmaniasis occurs in 88 countries, affecting 12 million people.

While the disease can be treated, current treatments are too expensive, difficult to administer, or toxic for widespread use in poor countries. Drug resistance is also a growing problem, particularly in India. Left untreated, VL has a 90% case fatality, and death can come within two yearsmuch more quickly than AIDS.

Furthermore, scientists warn that the geographical range for leishmaniasis is expanding. Spurred on by global warming, mass migration and rapid urbanization, cases are being reported in previously unaffected areas.

Given such challenges, a vacci
'/>"/>

Contact: Erik Iverson
media@idri.org
206-518-6280
Infectious Disease Research Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. New miniature grasshopper-like insect is first member of its family from Belize
2. St. Michaels and King Saud University receive first joint patent
3. First industrial-scale foam forming research environment for forest sector
4. St. Josephs receives Canadas first whole-body PET/MRI scanner
5. EASL publishes first European Clinical Practice Guidelines for Wilsons disease
6. First plants caused ice ages
7. UMass Amherst ecologists among the first to record and study deep-sea fish noises
8. Aria Diagnostics announces publication of first peer-reviewed data for new noninvasive prenatal test
9. OHSU research produces the worlds first primate chimeric offspring
10. UofL physicians, Jewish Hospital first in Kentucky to offer new aortic valve replacement
11. Simple blood test in the first trimester predicts fetal gender
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... an uphill battle? Try staying fit in space, where ... and bone. , That,s the challenge a group of ... three-year, $1.2 million grant from NASA. Their goal is ... missions. , "You could give astronauts the best exercise ... to stick to it, it isn,t going to help," ...
(Date:5/21/2013)... gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... resource assessment, market and policy developments, manufacturing and installation, ... and benefiting from its 2013 edition from a record ... 60 countries, more than 240 plenary and oral presentations, ...
(Date:5/21/2013)... The epigenetic modifications, which alter the way genes ... apparently be detected in the blood of pregnant ... way to foretell depression in the weeks after ... symptoms become debilitating. , The findings of the ... online in the journal Molecular Psychiatry . ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... times, cells sometimes resort to a form of self-cannibalism ... can have a down side, destroying the pancreas by ... swallows a portion of cytoplasm and ferries it to ... allowing hungry cells to recycle molecules, for example. However, ...
... known to be implicated in Crohn,s disease, a form of ... in the journal Nature Genetics , has identified a ... as providing surprising new links between the condition and other ... 1 in 500 and 1 in 1000 people within the ...
... throughout the world, resulting in large-scale ecosystem alteration and ... drought vary from year to year in severity and ... more severe conditions. Many modern varieties of potatoes ... cultivation in the cold, dry Andean Altiplano gave rise ...
Cached Biology News:Complexity of Crohn's disease revealed as 'gene' count tops 30 2Complexity of Crohn's disease revealed as 'gene' count tops 30 3Drought tolerance in potatoes 2Drought tolerance in potatoes 3
(Date:5/21/2013)... Belmont, MA (PRWEB) May 21, 2013 ... complete tracking to reporting eLearning solution using Tin ... report and dashboard tool. CLD is a leading ... biotech, and medical device companies worldwide. , ... tracking standard that helps learners and trainers more ...
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
(Date:5/21/2013)... New York , May 21, 2013 ... by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products ... Research, IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, ... 2.4 billion in 2011 and is expected to grow ... to reach an estimated value of USD 4.7 billion ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... 12 Two new white papers detailing,sterility ... download from,Microtest ( http://www.microtestlabs.com ). The white ... manufacturers and one which is specialized,for pharmaceutical ... with sterility testing and reviews different testing,methodologies. ...
... Sept. 12 Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical ... drugs in the areas of women,s health and,cancer, announced today ... at A.G. Edwards, 2nd Annual Emerging Growth Conference in New,York. ... ET on Tuesday,September 18, 2007 at the New York Palace ...
... 12 Genstruct Inc., a,biotechnology company translating the ... announced today that its president and,CEO, Dr. Keith ... the Oncology,Clinical Trial Summit in Arlington, Va., September ... panel discussion focused on,"Enhancing Development and Commercial Value ...
Cached Biology Technology:Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers 2Bionovo to Present at A.G. Edwards' 2nd Annual Emerging Growth Conference 2007 2Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2
... Peptide-Protein Conjugation, ... Bridges, Complex Peptides/Peptidomimetics, Special ... Phosphorylated/Biotinylated Structures, Peptide labeling AMC, ... -99%, fitting your needs, Chromogenic/Flurogenic ...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
...
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
Biology Products: